Hypertrophic cardiomyopathy (HCM) is a complex type of heart disease that affects the heart muscle. HCM causes thickening of the heart muscle (especially the ventricles, or lower heart chambers), left ventricular stiffness, mitral valve changes and cellular changes.
At Cleveland Clinic's Miller Family Heart, Vascular & Thoracic Institute, we have a special interest in treating Hypertrophic Cardiomyopathy (HCM). Since 1978, we have treated thousands of patients and the numbers are increasing each year.
What We Treat
Cleveland Clinic's Hypertrophic Cardiomyopathy Center is a multidisciplinary specialty treatment group dedicated to the diagnosis and treatment of HCM in individuals and family members. We bring together clinicians that specialize in HCM, including physicians and nurses from Cardiovascular Medicine, Genetics, Cardiothoracic Surgery, Pediatric Cardiology, and Psychology with expertise in diagnostic and genetic testing, medical management, and interventional and surgical procedures for patients with obstructive hypertrophic cardiomyopathy. In addition, we are involved in multiple research studies that provide patients with access to cutting edge novel therapies and diagnostic modalities.new method of diagnostic testing.
To learn more about other types of cardiomyopathy, see What is Cardiomyopathy?
Why choose Cleveland Clinic for your care?
Our outcomes speak for themselves. Please review our facts and figures and if you have any questions don't hesitate to ask.
Milind Desai, MD, MBA – Center Director
Our Medical Team
- Milind Desai, MD, MBA – Medical Director
- Nicholas Smedira, MD, MBA – Surgical Director
Cardiovascular Medicine and Imaging
Cardiovascular specialists use the latest techniques, such as tissue Doppler imaging, color M-Mode Doppler, transesophageal echocardiography, MR and CT help to diagnose hypertrophic cardiomyopathy and determine the best treatment. This group of physicians will evaluate you and begin to develop your plan of care. This will include risk stratification for sudden cardiac death as well as symptom relief from obstruction to flow of blood. Subsequently, based on your evaluation, they may refer you to their colleagues in electrophysiology, interventional cardiology and cardiothoracic surgery.
- Milind Desai, MD, MBA – Center Director
- Maran Thamilarasan, MD
- Zoran Popovic, MD, PhD
- Michael Emery, MD, Sports Cardiology
- Bo Xu, MD
- Jay Ramchand MD
- Susan Ospina, MSN, NP
Cardiovascular Medicine, Section of Electrophysiology and Pacing
In some patients, implantable cardioverter defibrillator (ICD) devices are required to prevent sudden death in patients with HCM. We have a team of electrophysiologists who specialize in rhythm disorders and devices who are consulted as needed for patients with HCM.
Cardiovascular Medicine, Section of Heart Failure and Transplantation
Some patients with hypertrophic cardiomyopathy may require evaluation by heart failure specialists to provide the best therapies for optimal treatment of heart failure.
Cardiovascular Medicine, Section of Invasive Cardiology
Interventionalists who are part of Hypertrophic Cardiomyopathy Center have experience with alcohol ablation, an interventional approach, used in select patients to treat septal enlargement in hypertrophic cardiomyopathy patients.
The surgical procedure for obstructive hypertrophic cardiomyopathy is called septal myectomy. In some cases, surgery may also be required to repair heart valves affected by HCM.
- Nicholas Smedira, MD, MBA – Surgical Director
- Kevin Hodges, MD
Our younger patients with hypertrophic cardiomyopathy require a specialized approached by a cardiologist pediatrician.
Pediatric & Congenital Heart Surgery
- Hani Najm, MD – Chair of Pediatric and Congenital Heart Surgery
- Tara Karamlou, MD
Other specialties are often needed to assist in evaluating family members with HCM or assisting with care or treatment of a condition. These medical professionals are experts in their field and have a particular specialty interest in the treatment of hypertrophic cardiomyopathy.
Cardiovascular Clinical Genetics
- Wilson Tang, MD
- Christina Rigelsky, MS, CGC
- Diane Clements, MS, CGC
- Brittany Psensky, MS, CGC
Learn more about Cardiovascular Clinical Genetics.
Psychiatry and Psychology
- Leopoldo Pozuelo, MD – Department of Psychiatry and Psychology
To make an appointment by phone:
New Patients: please call 216.442.9426 (216-442-9HCM) to speak to our Hypertrophic Cardiomyopathy Center team.
For follow up appointments, please call Cardiology Appointments at 216.444.6697 or call toll free 800.223.2273, extension 46697
Questions? We are here to answer your questions. Give us a call at 216.442.9426 (216-442-9HCM) or email email@example.com to speak to our Hypertrophic Cardiomyopathy Center team.
Or Request an Appointment online.
Use our secure online form to submit an appointment request 24/7. We will receive it and follow-up with you as soon as possible.
Mon. - Fri., 8 a.m. - 5 p.m. (ET):
toll-free 800.223.2273, ext. 49162
Also, can use 216-442-9HCM or firstname.lastname@example.org and your message will be returned within 1-2 business days.
Go to Desk J1 - 5, 9500 Euclid Avenue, Cleveland, Ohio.
What to Expect
Whether you are coming to Cleveland Clinic from around the corner or around the world, we want you to know what to expect before, during and after your visit. If you have any questions while reviewing this information, please contact us. We are happy to answer any questions you may have.
Before your appointment
If you are scheduled at least one week away, you will be asked to send in your records, including medical history, test results and films (such as echocardiogram, chest x-ray, MRI or CT as applicable). All information should be sent in the same package (clearly marked with your name and address) via Airborne Express, Federal Express, or certified U.S. mail (make sure you have a tracking number) to the physician with which you have an appointment. The address is:
Hypertrophic Cardiomyopathy Center
9500 Euclid Avenue – Desk J1 - 5
Cleveland, OH 44195
Learn other ways for Cleveland Clinic to obtain records through Care Everywhere, Fax and Image Upload
If you are scheduled less than one week out, please bring your records to your appointment.
Travel to Cleveland Clinic
When you make your appointment, we would like to make traveling to Cleveland Clinic as easy as possible. Information on travel to the Miller Family Heart, Vascular & Thoracic Institute.
During your appointment
You will meet with a nurse or a nurse practitioner (NP) who will collect your information, and begin the documentation process.
Depending on where you are in the diagnosis and treatment of your hypertrophic cardiomyopathy, you may be sent for specialized blood tests and imaging tests (electrocardiogram, comprehensive transthoracic echocardiogram, transesophageal echocardiogram, cardiac MR and multidetector CT scanning). All imaging tests will be interpreted by imaging specialists within the Hypertrophic Cardiomyopathy Center.
You will also meet with your HCM Center cardiologist who reviews your records and takes a medical history, performs a physical exam, and advises on consultations with other specialists (cardiac surgeons, invasive cardiologist, and others) within the Center as needed. If you need to meet with one of the multidisciplinary specialists, they will be consulted within a day. The Hypertrophic Cardiomyopathy Center Cardiologist will provide you with a diagnosis and plan of care within 1 to 2 days, depending on testing.
How long will you need to stay at Cleveland Clinic?
Unless a treatment is scheduled at the time of your visit, to complete all testing, you will need to stay in the Cleveland area for 1 to 2 days.
After your visit
Follow up is individualized to the patient. There is an opportunity for virtual visit follow-up as well.
Cleveland Clinic Heart, Vascular & Thoracic Institute physicians, surgeons, and researchers continue to research into new treatments and therapies with the goal of improving patient care and outcomes into the future.
Clinical trials (or research studies) help us create the medicine of tomorrow. They provide hope through offering testing of new drugs, new surgical techniques or other treatments before they are widely available.
We can help you access hundreds of clinical trials across all specialty areas. Our new searchable online trials tool makes identifying treatment opportunities easier than ever.
- A former Miss Ohio Advocates for Heart Health, Cleveland Magazine, 2020
- MyoKardia to Evaluate Mavacamten as an Alternative to Septal Reduction Therapy in Obstructive Hypertrophic Cardiomyopathy Patients, Global NewsWire, 2019
- Cleveland Clinic research study shows drug Mavacamten reduces the need for surgery in most patients, YouTube, 2022
- Cleveland Clinic Hypertrophic Cardiomyopathy Videos
- Current Concepts in Diagnosis and Management of Hypertrophic Cardiomyopathy, Cardiology Talk, 2021
- HCMA Bighearted Warriors Tour-Cleveland Clinic, YouTube, 2020
Please find a selection of publications from National Library of Medicine PubMed
- Characteristics and Outcomes of Elderly Patients With Hypertrophic Cardiomyopathy.
Alashi A, Smedira NG, Popovic ZB, Fava A, Thamilarasan M, Kapadia SR, Wierup P, Lever HM, Desai MY. Am Heart Assoc. 2021 Feb 2;10(3):e018527. doi: 10.1161/JAHA.120.018527. Epub 2021 Jan 28.PMID: 33506683 Free article.
- Impact of left atrial strain mechanics on exercise intolerance and need for septal reduction therapy in hypertrophic cardiomyopathy.
Saijo Y, Van Iterson E, Vega Brizneda M, Desai MY, Lever HM, Smedira NG, Wierup P, Thamilarasan M, Popović ZB, Grimm RA, Griffin BP, Xu B. Eur Heart J Cardiovasc Imaging. 2021 Jan 18:jeab001. doi: 10.1093/ehjci/jeab001. Online ahead of print.PMID: 33462591
- Outcomes in Guideline-Based Class I Indication Versus Earlier Referral for Surgical Myectomy in Hypertrophic Obstructive Cardiomyopathy.
Alashi A, Smedira NG, Hodges K, Popovic ZB, Thamilarasan M, Wierup P, Lever HM, Desai MY. J Am Heart Assoc. 2021 Jan 5;10(1):e016210. doi: 10.1161/JAHA.120.016210. Epub 2020 Dec 21.PMID: 33342243 Free article.
- Risk stratification using late gadolinium enhancement on cardiac magnetic resonance imaging in patients with hypertrophic cardiomyopathy: A systematic review and meta-analysis.
Kamp NJ, Chery G, Kosinski AS, Desai MY, Wazni O, Schmidler GS, Patel M, Lopes RD, Morin DP, Al-Khatib SM. Prog Cardiovasc Dis. 2020 Nov 7:S0033-0620(20)30181-X. doi: 10.1016/j.pcad.2020.11.001. Online ahead of print.PMID: 33171204 Review.
- Characteristics and Longer-Term Outcomes of Contemporary Patients <18 Years of Age With Hypertrophic Cardiomyopathy.
Alashi A, Svensson L, Klein J, Zahka K, Smedira NG, Najm H, Lever HM, Aziz P, Desai MY. Am J Cardiol. 2021 Feb 1;140:110-117. doi: 10.1016/j.amjcard.2020.10.060. Epub 2020 Nov 4.PMID: 33159906
- Mavacamten: a novel small molecule modulator of beta-cardiac myosin for treatment of hypertrophic cardiomyopathy.
Tower-Rader A, Ramchand J, Nissen SE, Desai MY. Expert Opin Investig Drugs. 2020
- Tricked by transient ischemic dilation: A case of hypertrophic cardiomyopathy.
Pristera N, Bhargava A. J Nucl Cardiol. 2020 Sep 10. doi: 10.1007/s12350-020-02350-7. Online ahead of print.PMID: 32914320 No abstract available.
- Surgical ablation of atrial fibrillation in hypertrophic obstructive cardiomyopathy: Outcomes of a tailored surgical approach.
Hodges K, Tang A, Rivas CG, Umana-Pizano J, Chemtob R, Desai MY, Gillinov AM, Smedira N, Wierup P. J Card Surg. 2020 Nov;35(11):2957-2964. doi: 10.1111/jocs.14946. Epub 2020 Aug 16.PMID: 33111447
- Waitlist and post- heart transplant outcomes for children with non-dilated cardiomyopathy.
Amdani S, Boyle G, Elizabeth S, Godown J, Liu W, Worley S, Karamlou T. Ann Thorac Surg. 2020 Aug 5:S0003-4975(20)31282-0. doi: 10.1016/j.athoracsur.2020.05.170. Online ahead of print.PMID: 32768427
- Robotic trans-mitral septal myectomy and papillary muscle reorientation for HOCM combined with or without mitral valve repair: Technical aspects - How we do it.
C J AK, Marc Gillinov A, Smedira NG, Hodges K, Burns DJP, Wierup P. J Card Surg. 2020 Nov;35(11):3120-3124. doi: 10.1111/jocs.14919. Epub 2020 Aug 2.PMID: 32740992
- Advanced imaging for risk stratification of sudden death in hypertrophic cardiomyopathy.
Ramchand J, Fava AM, Chetrit M, Desai MY. Heart. 2020 Jul;106(14):1111-1112. doi: 10.1136/heartjnl-2020-316770. Epub 2020 May 25.PMID: 32451363 No abstract available.
- A Validated Model for Sudden Cardiac Death Risk Prediction in Pediatric Hypertrophic Cardiomyopathy.
Miron A, Lafreniere-Roula M, Steve Fan CP, Armstrong KR, Dragulescu A, Papaz T, Manlhiot C, Kaufman B, Butts RJ, Gardin L, Stephenson EA, Howard TS, Aziz PF, Balaji S, Ladouceur VB, Benson LN, Colan SD, Godown J, Henderson HT, Ingles J, Jeewa A, Jefferies JL, Lal AK, Mathew J, Jean-St-Michel E, Michels M, Nakano SJ, Olivotto I, Parent JJ, Pereira AC, Semsarian C, Whitehill RD, Wittekind SG, Russell MW, Conway J, Richmond ME, Villa C, Weintraub RG, Rossano JW, Kantor PF, Ho CY, Mital S. Circulation. 2020 Jul 21;142(3):217-229. doi: 10.1161/CIRCULATIONAHA.120.047235. Epub 2020 May 18.PMID: 32418493 Free
- A Physician's Perspective on Generic Drug Quality.
Lever HM. J Manag Care Spec Pharm. 2020 May;26(5):592-593. doi: 10.18553/jmcp.2020.26.5.592.PMID: 32347170
- Association of Hypertrophic Obstructive Cardiomyopathy With Outcomes Following Transcatheter Aortic Valve Replacement.
Bandyopadhyay D, Chakraborty S, Amgai B, Kapadia SR, Braunwald E, Naidu SS, Kalra A. JAMA Netw Open. 2020 Feb 5;3(2):e1921669. doi: 10.1001/jamanetworkopen.2019.21669.PMID: 32083685 Free PMC article.
- Multimodality Imaging in Hypertrophic Cardiomyopathy for Risk Stratification.
Tower-Rader A, Kramer CM, Neubauer S, Nagueh SF, Desai MY. Circ Cardiovasc Imaging. 2020 Feb;13(2):e009026. doi: 10.1161/CIRCIMAGING.119.009026. Epub 2020 Feb 17.PMID: 32063056 Free PMC article.
- Advanced imaging for risk stratification of sudden death in hypertrophic cardiomyopathy.
Ramchand J, Fava AM, Chetrit M, Desai MY. Heart. 2020 Jun;106(11):793-801. doi:
- Clinical dilemmas in predicting the progression of pre-clinical hypertrophic cardiomyopathy-is MRI strain the solution?
Ramchand J, Desai MY. Ann Transl Med. 2019 Sep;7(Suppl 6):S177. doi: 10.21037/atm.2019.07.82.PMID: 31656756 Free PMC article. No abstract available.
- Regional Variability in Longitudinal Strain Across Vendors in Patients With Cardiomyopathy Due to Increased Left Ventricular Wall Thickness.
Sperry BW, Sato K, Phelan D, Grimm R, Desai MY, Hanna M, Jaber WA, Popović ZB. Circ Cardiovasc Imaging. 2019 Aug;12(8):e008973. doi: 10.1161/CIRCIMAGING.119.008973. Epub 2019 Aug 15.PMID: 31412719
- Different Histopathologic Diagnoses in Patients With Clinically Diagnosed Hypertrophic Cardiomyopathy After Surgical Myectomy.
Alashi A, Desai RM, Khullar T, Hodges K, Rodriguez ER, Tan C, Popovic ZB, Thamilarasan M, Wierup P, Lever HM, Smedira NG, Desai MY. Circulation. 2019 Jul 23;140(4):344-346. doi: 10.1161/CIRCULATIONAHA.119.040129. Epub 2019 Jul 22.PMID: 31329486 No abstract available.
- Impact of Obesity on Left Ventricular Thickness in Children with Hypertrophic Cardiomyopathy.
Balaji S, DiLorenzo MP, Fish FA, Etheridge SP, Aziz PF, Russell MW, Tisma S, Pflaumer A, Sreeram N, Kubus P, Law IH, Kantoch MJ, Kertesz NJ, Strieper M, Erickson CC, Moore JP, Nakano SJ, Singh HR, Chang P, Cohen M, Fournier A, Ilina MV, Smith RT, Zimmerman F, Horndasch M, Li W, Batra A, Liberman L, Hamilton R, Janson CM, Sanatani S, Zeltser I, McDaniel G, Blaufox AD, Garnreiter JM, Katcoff H, Shah M. Pediatr Cardiol. 2019 Aug;40(6):1253-1257. doi: 10.1007/s00246-019-02145-9. Epub 2019 Jul 1.PMID: 31263917
- Risk stratification in hypertrophic cardiomyopathy.
Desai M, Mentias A. Aging (Albany NY). 2019 Mar 28;11(6):1617-1618. doi: 10.18632/aging.101895.PMID: 30923259 Free PMC article. No abstract available.
- Surgical management of left ventricular outflow tract obstruction in a specialized hypertrophic obstructive cardiomyopathy center.
Hodges K, Rivas CG, Aguilera J, Borden R, Alashi A, Blackstone EH, Desai MY, Smedira NG. J Thorac Cardiovasc Surg. 2019 Jun;157(6):2289-2299. doi: 10.1016/j.jtcvs.2018.11.148. Epub 2018 Dec 29.PMID: 30782406
- Alcohol: Keep it moderate.
Smedira NG. J Thorac Cardiovasc Surg. 2019 Jan;157(1):304-305. doi: 10.1016/j.jtcvs.2018.10.054. Epub 2018 Oct 22.PMID: 30557948 No abstract available.
- Prognostic Value of Global Longitudinal Strain in Hypertrophic Cardiomyopathy: A Systematic Review of Existing Literature.
Tower-Rader A, Mohananey D, To A, Lever HM, Popovic ZB, Desai MY. JACC Cardiovasc Imaging. 2019 Oct;12(10):1930-1942. doi: 10.1016/j.jcmg.2018.07.016. Epub 2018 Sep 12.PMID: 30219395 Free article.
- Hypertrophic cardiomyopathy: A complex disease.
Young L, Smedira NG, Tower-Rader A, Lever H, Desai MY. Cleve Clin J Med. 2018 May;85(5):399-411. doi: 10.3949/ccjm.85a.17076.PMID: 29733784 Review.
- Prediction of sudden death risk in obstructive hypertrophic cardiomyopathy: Potential for refinement of current criteria.
Desai MY, Smedira NG, Dhillon A, Masri A, Wazni O, Kanj M, Sato K, Thamilarasan M, Popovic ZB, Lever HM. J Thorac Cardiovasc Surg. 2018 Aug;156(2):750-759.e3. doi: 10.1016/j.jtcvs.2018.03.150. Epub 2018 Apr 12.PMID: 29735354